Table 3.
Crude and Adjusted Hazard Ratio (HR) Estimates for Incident Liver Cirrhosis under Alternative Outcome Definitions (365-Day Washout Period, As-Treated Analysis, 1% Asymmetric Propensity Score Trimming)
| High Specificity Definitionsa | High Sensitivity Definitionsa | |||||||
|---|---|---|---|---|---|---|---|---|
| Comparison | Cohort | Number of Patients | Crude Incidence Rate, per 1,000 Person-Years | Crude HR (95% CI) | PS-weighted HR (95% CI) | Crude Incidence Rate, per 1,000 Person-Years | Crude HR (95% CI) | PS-weighted HR (95% CI) |
| DPP4i vs. TZD | ||||||||
| Lapointe et al, 2018 | DPP4i | 69027 | 2.8 (2.4–3.2) | 1.09 (0.86–1.39) | 1.15 (0.89–1.50) | 6.2 (5.7–6.8) | 1.34 (1.13–1.59) | 1.38 (1.14–1.66) |
| Definitions 1 & 2 | TZD | 34464 | 2.6 (2.1–3.1) | 4.6 (4.0–5.4) | ||||
| Nehra et al, 2013 | DPP4i | 69027 | 1.0 (0.8–1.2) | 1.03 (0.69–1.52) | 1.03 (0.68–1.56) | 6.9 (6.3–7.5) | 1.20 (1.02–1.40) | 1.25 (1.05–1.48) |
| Definitions 3 & 4 | TZD | 34464 | 1.0 (0.7–1.3) | 5.8 (5.1–6.6) | ||||
| GLP1RA vs. TZD | ||||||||
| Lapointe et al, 2018 | GLP1RA | 10728 | 3.6 (2.5–5.2) | 1.41 (0.95–2.11) | 1.34 (0.82–2.20) | 7.0 (5.4–9.1) | 1.37 (1.03–1.83) | 1.21 (0.85–1.70) |
| Definitions 1 & 2 | TZD | 41745 | 2.6 (2.2–3.2) | 4.9 (4.3–5.6) | ||||
| Nehra et al, 2013 | GLP1RA | 10728 | 1.9 (1.2–3.2) | 1.93 (1.09–3.41) | 1.77 (0.79–3.97) | 8.3 (6.5–10.5) | 1.32 (1.02–1.73) | 1.19 (0.86–1.65) |
| Definitions 3 & 4 | TZD | 41745 | 1.0 (0.7–1.3) | 5.9 (5.3–6.7) | ||||
| SGLT2i vs. TZD | ||||||||
| Lapointe et al, 2018 | SGLT2i | 7849 | 1.7 (0.8–3.6) | 0.91 (0.38–2.21) | 1.16 (0.44–3.08) | 7.8 (5.5–11.1) | 1.48 (0.92–2.39) | 1.64 (0.94–2.86) |
| Definitions 1 & 2 | TZD | 10980 | 2.0 (1.2–3.2) | 4.8 (3.6–6.6) | ||||
| Nehra et al, 2013 | SGLT2i | 7849 | 0.7 (0.2–2.3) | 1.04 (0.26–4.17) | 1.99 (0.49–8.02) | 7.8 (5.5–11.1) | 1.28 (0.81–2.04) | 1.38 (0.80–2.38) |
| Definitions 3 & 4 | TZD | 10980 | 0.8 (0.4–1.7) | 5.5 (4.2–7.4) | ||||
Abbreviations: SGLT2i, sodium-glucose cotransporter-2 inhibitors; DPP4i, dipeptidyl peptidase-4 inhibitors; GLP1RA, glucagon-like peptide-1 receptor agonists; TZD, thiazolidinediones; IQR, interquartile range; PS, propensity score; AT, as-treated; IT, initial treatment (similar to intention-to-treat approach in randomized controlled trials)
Definition 1: 456.1; 571.2; 571.5; INPATIENT ONLY (specificity 91–96%; sensitivity 57–77%)
Definition 2: 456.1; 571.2; 571.5; INPATIENT (INPT) & OUTPATIENT (OUTPT) (specificity 61–77%; sensitivity 98–99%)
Definition 3: 456.0; 456.2; 456.21; 572.4; INPT/OUTPT (specificity 98.3%; sensitivity 11.3%)
Definition 4: 456.0; 456.1; 456.2; 456.21; 571.2; 571.5; 572.2; 572.3; 572.4; 567.23; INPT/OUTPT (specificity 43%; sensitivity 97.7%)